Clinical Trial Update: Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sotagliflozin in type 2 diabetes with moderate renal impairment at cardiovascular risk; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Sotagliflozin (sotagliflozin)

Snippet

Sponsor: Lexicon Pharmaceuticals | Conditions: Heart Failure, Type 2 Diabetes Mellitus | Phase 3 | Status: TERMINATED | Results posted: 2022-10-28